Results 141 to 150 of about 11,335 (243)

Computational modeling of PROTAC ternary complexes as ensembles using SILCS-PROTAC

Modeling ternary complexes is a critical and challenging problem. Proteolysis targeting chimeras, or PROTACs, are an emerging class of drugs that offer the potential to develop therapeutics targeting “undruggable” proteins by stabilizing ternary complexes.
Erik Nordquist, Mingtian Zhao, Wenbo Yu, Alex MacKerell   +3 more
openaire   +1 more source

PROTAC-Mediated Degradation of mHTT Aggregates Attenuates Neurotoxicity in Cellular and R6/2 Mouse Models of Huntington's Disease. [PDF]

J Am Chem Soc
Lu PC, Huang YA, Wali N, Tseng MC, He RY, Chern Y, Wei TT, Shie JJ, Huang JJ.   +8 more
europepmc   +1 more source

PROTAC-mediated multi-target protein degradation in Alzheimer's disease: mechanistic insights, therapeutic applications, and translational challenges. [PDF]

RSC Med Chem
Wang B, Li Y, Yao T, Shen X, Li H, Jiang W, Li X, Zhu Z.   +7 more
europepmc   +1 more source

Data-Driven Design of PROTAC Linkers to Improve PROTAC Cell Membrane Permeability. [PDF]

JACS Au
Murakami Y, Ishida S, Cho N, Yuki H, Ohta M, Honma T, Demizu Y, Terayama K.   +7 more
europepmc   +1 more source

Unveiling BCL-xL-specific PROTAC efficiency and dissociation pathways using native mass spectrometry. [PDF]

Chem Sci
Gadallah MI, Nonhof KL, Nayak D, Zhang P, Dioli O, Zheng G, Olsen SK, Zhou D, Brodbelt JS.   +8 more
europepmc   +1 more source

PROTAC-Mediated Ternary Complex Stability with Ricin Toxin A: A Computational Perspective. [PDF]

ACS Omega
Botelho FD, Islam ST, LaPlante SR, Franca TCC.   +3 more
europepmc   +1 more source

Protacs in oral cancer: degrading oncogenic drivers for next-generation therapy. [PDF]

Front Oral Health
Prasad P, Al Maslamani MJ, Dinislam K, Tasqeruddin S, Shamsi A.   +4 more
europepmc   +1 more source

PROTAC approaches against drug-resistant EGFR^{C797S/L858R/T790M} mutants: biological evaluation and SAR studies (2020-2025). [PDF]

RSC Med Chem
Kumar A, Sharma V, Kumari P, Kaur R, Bhatia R.   +4 more
europepmc   +1 more source

Editorial: Next-generation PROTACs in oncology and beyond: exploring therapeutic targets and their degraders. [PDF]

Front Pharmacol
Liao D, Bandyopadhyay D.
europepmc   +1 more source

EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2. [PDF]

Oncogene
Xie W, Chu Q, Brea L, Zeng G, Wang Y, Lu X, Zheng M, Ley CR, Lei Z, Shi H, Zhu JL, Gong L, Martin MC, Shi X, Gritsina G, Grigorescu AA, Chandonnet H, Liu X, Zhao JC, Schiltz GE, Yu J.   +20 more
europepmc   +1 more source